Rockefeller Capital Management
MTNB icon

Rockefeller Capital Management’s Matinas BioPharma MTNB Stock Holding History

Rockefeller Capital Management’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-500
Closed -$945 – 4782
2025
Q3 		$945 Buy
+500
New +$719 ﹤0.01% 4193

Other funds holding MTNB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return
HIW
Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Rockefeller Capital Management's MTNB Position: Q4 2025 in Review

Rockefeller Capital Management sold out of Matinas BioPharma (MTNB) in Q4 2025, closing a stake of 500 shares — an estimated $945 sold.

Rockefeller Capital Management first reported a position in MTNB in Q3 2025 and held it in 1 quarter. The position peaked at $945 in Q3 2025. 30 funds tracked by Wall St. Rank hold MTNB as of Q4 2025.

  • Rockefeller Capital Management reported no remaining Matinas BioPharma position as of Q4 2025 after selling out during the quarter.
  • Rockefeller Capital Management sold 500 Matinas BioPharma shares in Q4 2025, an estimated $945.
  • Rockefeller Capital Management first reported a position in Matinas BioPharma in Q3 2025 and held it in 1 quarter.
  • Rockefeller Capital Management's Matinas BioPharma position peaked at $945 in Q3 2025.
  • 30 funds tracked by Wall St. Rank held Matinas BioPharma as of Q4 2025.

Based on Rockefeller Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.